Prediction of Response to Hormone Therapy in Prostate Cancer by Bromodeoxyuridine Labeling

点击翻译按钮获取中文摘要

It is very beneficial to predict the efficacy of medical treatments for cancer such as the hormone treatment for prostate cancer or the chemotherapy for bladder or renal cancer. The labeling index of bromodeoxyuridine (BrdU), which is a marker of DNA synthesis in cells, was measured both before and after the treatment in tissues of urological malignancies. For this purpose we developed a new device for labeling tissues with BrdU. The device, composed of a syringe and a container, made it possible to labeling the tissue in vitro easier and more promptly than before. Thirteen patients with prostate cancer, 10 with bladder cancer and 2 with renal cancer were examined. In all the prostate cancer patients, the labeling index was much decreased after the hormone treatment. Four patients showed the labeling indexes greater than 2 per cents although many of others showed no labeled cells. Three of the 4 patients encountered progression or early relapse of the disease. On the other hand, patients with no labeling cells had no recurrence or progression.There were no significant findings on bladder cancer or renal cancer because the number of cases in this series was very limited.